Under the chosen conditions, ERK phosphorylation and activity (assessed through the surrogate marker DUSP6) was reduced with BRAF inhibitor (Fig 6C), but the combination treatment led to a significant further reduction, supporting the idea that EDNRB signalling contributes to ERK activation within these tumours. Here, DUSP6 is linked to neoplasm.